MDT

86.05

+0.2%↑

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

MDT

86.05

+0.2%↑

114.6

+0.02%↑

VEEV

173.01

-0.02%↓

HQY

84.23

+1.14%↑

PHR.US

8.4

-1.18%↓

Kodu・Aktsiate loetelu・Vaxart Inc

Vaxart Inc

Avatud

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad
By Trading Economics
Sissetulek	63M 55M
Müük	32M 104M
P/E Sektori keskmine	8.571 56.063
Aktsiakasum	0.24
Kasumimarginaal	52.807
Töötajad	65
EBITDA	63M 58M

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	12. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-47M 144M
Eelmine avamishind	0
Eelmine sulgemishind	0

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.4007 / 0.4252 Toetus ja vastupanu

Vaxart Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2026, 22:56 UTC

Uudisväärsed sündmused

Australian PM Set To Announce Interest-Free Loans For Businesses, Farmers

1. apr 2026, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Deadline on Tender Offer to Acquire Arcellx

1. apr 2026, 23:55 UTC

Market Talk

Gold Rises on Hopes for Early End to U.S.-Iran Conflict -- Market Talk

1. apr 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Continued Hopes for U.S. Ending Iran War -- Market Talk

1. apr 2026, 23:23 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock -- Update

1. apr 2026, 23:07 UTC

Tulu

Shake Shack Leans on Loyalty Program and Tech to Drive Growth -- Barrons.com

1. apr 2026, 23:02 UTC

Uudisväärsed sündmused

South Korea Consumer Inflation Accelerates on Mideast Energy Shock

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +0.3% on Month; +0.6% Forecast

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar Core CPI +2.2% on Year, +0.1% on Month

1. apr 2026, 23:00 UTC

Uudisväärsed sündmused

S Korea Mar CPI +2.2% on Year; +2.4% Forecast

1. apr 2026, 22:39 UTC

Tulu

Nike Can't Fix Its China Problem and That's Tanking Its Stock -- Update

1. apr 2026, 22:08 UTC

Market Talk

KKR BDC Joins Others in Capping Withdrawals at 5% -- Market Talk

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Mideast War Rekindles Asia Inflation Risk, Says DBS Chief Economist -- Interview

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Rate Hikes Seem Likely in Japan, Singapore, Australia

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: BOK Could Also Take Proactive Approach Like RBA

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: India Vulnerable to War Imapct on Both Trade, Energy

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: China, Malaysia Looks Relatively Well-Insulated From War Fallout

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

DBS Chief Economist: Mideast Crisis Won't Hurt Asia Growth Much, Inflation a Bigger Issue

1. apr 2026, 22:00 UTC

Uudisväärsed sündmused

Inflationary Impact of Mideast Conflict Seems Inevitable, DBS Group Chief Economist Says

1. apr 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

BHP Completes $4.3 Billion Silver Streaming Agreement With Wheaton Precious Metals

1. apr 2026, 21:31 UTC

Uudisväärsed sündmused

End to Iran War Could Trigger Relief Rally in These 2 Assets -- Barrons.com

1. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. apr 2026, 20:38 UTC

Tulu

Why Nike Stock Is in 'Penalty Box' After Earnings Beat -- Barrons.com

1. apr 2026, 20:31 UTC

Omandamised, ülevõtmised, äriostud

Arsenal Capital Partners Completes Sale of ATP Adhesive Systems to Henkel

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Tender Offer Extended to Expire at 5 p.m. EDT on April 24 >GILD

1. apr 2026, 20:16 UTC

Omandamised, ülevõtmised, äriostud

Gilead: Offer Remains at a Purchase Price of $115.00 per Shr >GILD

1. apr 2026, 20:13 UTC

Omandamised, ülevõtmised, äriostud

Gilead Extends Tender Offer To Acquire Arcellx >GILD

1. apr 2026, 20:07 UTC

Market Talk

Mexican Manufacturing Indexes Pick Up in March -- Market Talk

1. apr 2026, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Why 2026 Is Biotech's Comeback Year -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Vaxart Inc Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Vaxart Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.4007 / 0.4252Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Vaxart Inc

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.